异基因造血细胞移植后男性地中海贫血患者的自发生育

IF 0.6 Q4 HEMATOLOGY
N. Iacovidou, M. Kollia, E. Nana, T. Boutsikou, C. Savvidis, A. Kattamis, D. Kyriakopoulou, V. Ladis
{"title":"异基因造血细胞移植后男性地中海贫血患者的自发生育","authors":"N. Iacovidou, M. Kollia, E. Nana, T. Boutsikou, C. Savvidis, A. Kattamis, D. Kyriakopoulou, V. Ladis","doi":"10.4081/THAL.2017.7090","DOIUrl":null,"url":null,"abstract":"Patients with thalassemia major who received allogeneic hematopoietic cell transplantation are at increased risk of gonadal insufficiency and reduced fertility due to the toxicity of both the transfusional iron overload and the gonadotoxic effects of drugs used in the conditioning regimen. We present a case of an ex-thalassemic patient with spontaneous recovery of spermatogenesis that fathered a healthy, term male neonate. Maternal hemoglobin electrophoresis was within normal limits. At the age of 9.5 years the patient underwent hematopoietic cell transplantation. The conditioning therapy included busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg). No irradiation was administered. Thirty-two days after the hematopoietic cell transplantation the patient developed acute graft-versus-host disease needing long-term treatment with methylprednisolone, cyclosporine and immunoglobulin. Although consecutive semen analyses after the hematopoietic cell transplantation revealed azoospermia, the last semen analysis before conception, at the age of 33 years, was improved and normal follicle stimulating hormone (FSH), luteinizing hormone (LH) and testosterone (Te) levels were detected. The current pregnancy was the result of physical conception. In this case, it seems that thalassemia major along with the respective treatment prior to- and posthematopoietic cell transplantation did not irreparably impair spermatogenesis, probably due to the pre-pubertal time frame they were implemented. 对于接受异基因造血细胞移植的重型地中海贫血患者,由于输注性铁过载的毒性和预处理方案中所用药物性腺毒性作用这两方面的原因,都使其面临更大的性腺功能不全风险和更低的生育力。本文报道一例精子发生出现自然恢复的原重型地中海贫血患者,他成功孕育出一个健康的足月男婴。母体血红蛋白电泳在正常范围内。患者在9岁半时接受了造血细胞移植。预处理治疗包括白消安(16 mg/kg)和环磷酰胺(200 mg/kg)。未给予照射。造血细胞移植32天后,患者出现急性移植物抗宿主病,需要长期使用甲基强的松龙、环孢素和免疫球蛋白治疗。虽然造血细胞移植后连续的精液分析显示无精子症,但在33岁时受精前的最后一次精液分析有所改善,经检测发现卵泡刺激素(FSH)、黄体生成素(LH)和睾酮(Te)水平正常。目前的怀孕是自然受孕的结果。在这个病例中,看来重型地中海贫血以及造血细胞移植前后相应的治疗并没有对精子发生造成不可恢复的破坏,这可能是由于移植时处于青春发育期前时间段的原因。","PeriodicalId":22261,"journal":{"name":"Thalassemia Reports","volume":" ","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2017-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/THAL.2017.7090","citationCount":"0","resultStr":"{\"title\":\"Spontaneous fertility in a male thalassemic patient after allogeneic hematopoietic cell transplantation\",\"authors\":\"N. Iacovidou, M. Kollia, E. Nana, T. Boutsikou, C. Savvidis, A. Kattamis, D. Kyriakopoulou, V. Ladis\",\"doi\":\"10.4081/THAL.2017.7090\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patients with thalassemia major who received allogeneic hematopoietic cell transplantation are at increased risk of gonadal insufficiency and reduced fertility due to the toxicity of both the transfusional iron overload and the gonadotoxic effects of drugs used in the conditioning regimen. We present a case of an ex-thalassemic patient with spontaneous recovery of spermatogenesis that fathered a healthy, term male neonate. Maternal hemoglobin electrophoresis was within normal limits. At the age of 9.5 years the patient underwent hematopoietic cell transplantation. The conditioning therapy included busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg). No irradiation was administered. Thirty-two days after the hematopoietic cell transplantation the patient developed acute graft-versus-host disease needing long-term treatment with methylprednisolone, cyclosporine and immunoglobulin. Although consecutive semen analyses after the hematopoietic cell transplantation revealed azoospermia, the last semen analysis before conception, at the age of 33 years, was improved and normal follicle stimulating hormone (FSH), luteinizing hormone (LH) and testosterone (Te) levels were detected. The current pregnancy was the result of physical conception. In this case, it seems that thalassemia major along with the respective treatment prior to- and posthematopoietic cell transplantation did not irreparably impair spermatogenesis, probably due to the pre-pubertal time frame they were implemented. 对于接受异基因造血细胞移植的重型地中海贫血患者,由于输注性铁过载的毒性和预处理方案中所用药物性腺毒性作用这两方面的原因,都使其面临更大的性腺功能不全风险和更低的生育力。本文报道一例精子发生出现自然恢复的原重型地中海贫血患者,他成功孕育出一个健康的足月男婴。母体血红蛋白电泳在正常范围内。患者在9岁半时接受了造血细胞移植。预处理治疗包括白消安(16 mg/kg)和环磷酰胺(200 mg/kg)。未给予照射。造血细胞移植32天后,患者出现急性移植物抗宿主病,需要长期使用甲基强的松龙、环孢素和免疫球蛋白治疗。虽然造血细胞移植后连续的精液分析显示无精子症,但在33岁时受精前的最后一次精液分析有所改善,经检测发现卵泡刺激素(FSH)、黄体生成素(LH)和睾酮(Te)水平正常。目前的怀孕是自然受孕的结果。在这个病例中,看来重型地中海贫血以及造血细胞移植前后相应的治疗并没有对精子发生造成不可恢复的破坏,这可能是由于移植时处于青春发育期前时间段的原因。\",\"PeriodicalId\":22261,\"journal\":{\"name\":\"Thalassemia Reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2017-11-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.4081/THAL.2017.7090\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Thalassemia Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/THAL.2017.7090\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thalassemia Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/THAL.2017.7090","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

Patients with Thalassemia major who received allogenic hematological cell transplantation are at an increased risk of governmental inefficiency and reduced utility due to the toxicity of both the transitional iron overload and the Gonadoxic effects of drugs used in the conditioning region We present a case of an ex-thalasemic patient with sparse recovery of spermatogenes that fathered a health, term male neonate Material hemoglobin electrophoresis was within normal limits At the age of 9.5 years the patient underneath hematological cell transmission The conditioning therapy includes busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) No iration was administered Third two days after the hematopoietic cell transmission of the patient developed acute gradient Versus host disease needing long term treatment with methylprednisolone, cyclosporine, and immunoglobal Although consecutive semen analyses after the hematopoietic cell transmission revised azoospermia, the last semen analysis before concept, at the age of 33 years, was improved and normal follicular stimulating hormone (FSH), luteinizing hormone (LH) and testosterone (Te) levels were detected The current reservation was the result of physical concept In this case, it appears that that assembly major along with the prospective treatment prior to - and postdoctoral cell transplantation did not irreparably improve sperm genes, possibly due to the pre public time frame they were implemented For patients with severe thalassemia undergoing allogeneic hematopoietic cell transplantation, due to the toxicity of iron overload during infusion and the gonadal toxicity of the drugs used in the pre-treatment regimen, they face a greater risk of gonadal dysfunction and lower fertility. This article reports a case of a patient with severe thalassemia who experienced natural recovery after spermatogenesis. He successfully gave birth to a healthy full-term male infant. The maternal hemoglobin electrophoresis is within the normal range. The patient received a hematopoietic cell transplant at the age of 9 and a half. Preconditioning treatment includes Baixiaoan (16 mg/kg) and cyclophosphamide (200 mg/kg). No irradiation was given. After 32 days of hematopoietic cell transplantation, the patient developed acute graft versus host disease and required long-term treatment with methylprednisolone, cyclosporine, and immunoglobulin. Although continuous semen analysis after hematopoietic cell transplantation showed azoospermia, the last semen analysis before fertilization improved at the age of 33, and normal levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), and testosterone (Te) were detected. The current pregnancy is the result of natural conception. In this case, it appears that severe thalassemia and the corresponding treatment before and after hematopoietic cell transplantation did not cause irreparable damage to spermatogenesis, which may be due to the pre pubertal period during transplantation.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Spontaneous fertility in a male thalassemic patient after allogeneic hematopoietic cell transplantation
Patients with thalassemia major who received allogeneic hematopoietic cell transplantation are at increased risk of gonadal insufficiency and reduced fertility due to the toxicity of both the transfusional iron overload and the gonadotoxic effects of drugs used in the conditioning regimen. We present a case of an ex-thalassemic patient with spontaneous recovery of spermatogenesis that fathered a healthy, term male neonate. Maternal hemoglobin electrophoresis was within normal limits. At the age of 9.5 years the patient underwent hematopoietic cell transplantation. The conditioning therapy included busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg). No irradiation was administered. Thirty-two days after the hematopoietic cell transplantation the patient developed acute graft-versus-host disease needing long-term treatment with methylprednisolone, cyclosporine and immunoglobulin. Although consecutive semen analyses after the hematopoietic cell transplantation revealed azoospermia, the last semen analysis before conception, at the age of 33 years, was improved and normal follicle stimulating hormone (FSH), luteinizing hormone (LH) and testosterone (Te) levels were detected. The current pregnancy was the result of physical conception. In this case, it seems that thalassemia major along with the respective treatment prior to- and posthematopoietic cell transplantation did not irreparably impair spermatogenesis, probably due to the pre-pubertal time frame they were implemented. 对于接受异基因造血细胞移植的重型地中海贫血患者,由于输注性铁过载的毒性和预处理方案中所用药物性腺毒性作用这两方面的原因,都使其面临更大的性腺功能不全风险和更低的生育力。本文报道一例精子发生出现自然恢复的原重型地中海贫血患者,他成功孕育出一个健康的足月男婴。母体血红蛋白电泳在正常范围内。患者在9岁半时接受了造血细胞移植。预处理治疗包括白消安(16 mg/kg)和环磷酰胺(200 mg/kg)。未给予照射。造血细胞移植32天后,患者出现急性移植物抗宿主病,需要长期使用甲基强的松龙、环孢素和免疫球蛋白治疗。虽然造血细胞移植后连续的精液分析显示无精子症,但在33岁时受精前的最后一次精液分析有所改善,经检测发现卵泡刺激素(FSH)、黄体生成素(LH)和睾酮(Te)水平正常。目前的怀孕是自然受孕的结果。在这个病例中,看来重型地中海贫血以及造血细胞移植前后相应的治疗并没有对精子发生造成不可恢复的破坏,这可能是由于移植时处于青春发育期前时间段的原因。
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Thalassemia Reports
Thalassemia Reports HEMATOLOGY-
自引率
0.00%
发文量
17
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信